Episode 514: Blockbuster News About Lipoprotein(a) Therapy

This week, Dr. Kahn discusses the widespread disappointment following Novartis' announcement that its 8,000-patient HORIZON trial of a lipoprotein(a)-lowering drug failed to meet its primary endpoint. The news came as a major surprise and disappointment to patients eagerly awaiting access to this medication. No additional details have been released, and there is not yet a published paper to review. Dr. Kahn discusses the possible reasons the trial failed and what he plans to do moving forward. Other topics include lifestyle factors associated with sudden cardiac arrest, mindfulness for elevated blood pressure, hormone therapy and the female brain during menopause, the risks of off-label testosterone therapy in men, GLP-1 medications and lifespan, Mounjaro and cardiovascular risk, TMAO and brain atrophy, statins and reduced dementia risk, and the connection between adverse pregnancy outcomes and future cardiovascular disease.  Dr. Kahn's new book, Don't Drop Dead, is available in print, audiobook, and Kindle formats on Amazon.  Finally, thanks to WellBean and its amazing bean bars. Use promo code DrKahn15 to save money on your order.